 | | Vol. 11.18 – 12 May, 2022 |
| |
|
|
Histone H3K9 Methyltransferase SETDB1 Augments Invadopodia Formation to Promote Tumor Metastasis | Researchers demonstrated that SETDB1 augmented the migration and invasion capabilities of NSCLC cells by reinforcing invadopodia formation and mediated ECM degradation.
[Oncogene] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
Rapid and Efficient Testing of the Toxicity of Graphene-Related Materials in Primary Human Lung Cells | RScientists proposed an in vitro model using primary, non-transformed normal human bronchial epithelial cells as an alternative to the most widely used model to date, the human lung tumor cell line A549.
[Scientific Reports] |
|
|
|
SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells | Investigators found that depletion of IFITM2 strongly reduced viral RNA production by all “variants of concern” in the human epithelial lung cancer cell line Calu-3.
[Journal of Virology] |
| |
|
|
E3 Ligase TRIM15 Facilitates Non-Small Cell Lung Cancer Progression through Mediating Keap1-Nrf2 Signaling Pathway | Scientists reported that tripartite motif 15 (TRIM15) played important roles in NSCLC progression through modulating Keap1-Nrf2 signaling pathway.
[Cell Communication and Signaling] |
|
|
|
Fatty Acid Binding Protein 5 Regulates Lipogenesis and Tumor Growth in Lung Adenocarcinoma | By radioactive labeling and metabolite quantification, the authors studied the function of fatty acid binding protein 5 in fatty acid metabolism using genetic/pharmacologic inhibition and overexpression models in lung adenocarcinoma cell lines.
[Life Sciences] |
|
|
|
PAFAH1B3 Predicts Poor Prognosis and Promotes Progression in Lung Adenocarcinoma | Scientists indicated that platelet-activating factor acetylhydrolase 1b catalytic subunit 3 (PAFAH1B3), a prognostic risk factor, promoted proliferation, invasion and epithelial-to-mesenchymal transition and affected immune infiltrates in lung adenocarcinoma.
[BMC Cancer] |
|
|
|
Combining Radiation with PI3K Isoform-Selective Inhibitor Administration Increases Radiosensitivity and Suppresses Tumor Growth in Non-Small Cell Lung Cancer | Investigators assessed whether combining radiation with the administration of the phosphoinositide 3-kinase (PI3K) isoform-selective inhibitors reduced radioresistance and tumor growth in NSCLC.
[Journal of Radiation Research] |
|
|
|
A Targeted siRNA-Loaded PDL1-Exosome and Functional Evaluation against Lung Cancer | An exosome was used as the siRNA-loaded substrate to prepare a targeted siRNA-loaded PD-L1 exosome and evaluate its function against lung cancer.
[Thoracic Cancer] |
|
|
|
ACT001 Inhibits the Proliferation of Non-Small Cell Lung Cancer Cells by Upregulating NKTR Expression | The authors investigated the effect of ACT001, a novel sesquiterpene lactone derivative, on the proliferation of NSCLC cells and explored the underlying mechanism.
[Thoracic Cancer] |
|
|
|
Knockdown of Ubiquitin-Conjugating Enzyme E2T (UBE2T) Suppresses Lung Adenocarcinoma Progression via Targeting Fibulin-5 (FBLN5) | UBE2T may be a potential biomarker of lung adenocarcinoma (LUAD), and targeting the UBE2T/FBLN5 axis may be a novel treatment strategy for LUAD.
[Bioengineered] |
|  |
|
|
|
The Relationship between Previous Pulmonary Tuberculosis and Risk of Lung Cancer in the Future | It is becoming clearer that Mycobacterium tuberculosis in tuberculosis patients meticulously schemes multiple mechanisms to induce tumor formation and is indispensable to participate in the occurrence of lung cancer.
[infectious Agents and Cancer] |
|
|
|
Baicalein: A Review on Its Anti-Cancer Effects and Mechanisms in Lung Carcinoma | Baicalein has been studied for its several biological effects including antioxidant, anti-inflammatory, anti-hepatotoxic, antiviral, and anti-tumor properties.
[Journal of Food Biochemistry] |
|
|
|
|
Mereo BioPharma Announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase II Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency- Associated Emphysema | Mereo BioPharma Group plc announced positive top-line efficacy and safety results from “ASTRAEUS” a Phase II study of the investigational oral neutrophil elastase inhibitor, alvelestat, in patients with severe alpha-1 antitrypsin deficiency-associated emphysema.
[Mereo BioPharma Group plc] |
|
|
|
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung Cancer | Imago BioSciences, Inc. announced that the first participant has been treated in an investigator-sponsored Phase I/II study of bomedemstat in combination with atezolizumab during the maintenance phase of treatment in people newly diagnosed with extensive stage small cell lung cancer.
[Imago BioSciences, Inc.] |
|
|
|
|
| September 19 – 20, 2022
Vejle, Denmark |
|
|
|
|
|
| | Francis Crick Institute – London, United Kingdom |
|
|
|
| | Flanders Institute for Biotechnology – Brussels, Belgium |
|
|
|
| | Mayo Clinic – Scottsdale, Arizona, United States |
|
|
|
| | Gilead Sciences, Inc. – Foster City, California, United States |
|
|
|
| | McGill University – Montreal, Quebec, Canada |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
